Ozurdex in Suboptimal Diabetic Macular Edema Patients
Status:
Not yet recruiting
Trial end date:
2021-12-29
Target enrollment:
Participant gender:
Summary
The primary focus of this study is to understand the anatomic and visual outcomes of patients
with refractory and suboptimal treatment response diabetic macular edema (DME) using
anti-vascular endothelial growth factor (VEGF) to Ozurdex, an intravitreal dexamethasone
implant. Secondly, investigators aim to understand the differences in cytokine profiles in
patients who respond differently to intravitreal anti-VEGF versus Ozurdex. The importance of
this study is to identify biomarkers that may help predict patients' response to different
treatment protocols. Currently, Ozurdex is not covered by provincial health benefit plans for
patients with DME. Our results may help improve access to care for those who have suboptimal
results with or refractory to intravitreal anti-VEGF treatment.